1-Carbamoylpiperidine-3-carboxylic acid | 871478-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Carbamoylpiperidine-3-carboxylic acid
• CAS: 871478-82-9
• 化学式: C₇H₁₂N₂O₃
• mdl: MFCD06799728
• 分子量: 172.18
• InChiKey: CRCXZDRNTOBHLY-UHFFFAOYSA-N

物化性质

• 沸点：
  372.8±52.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF
  申请人：Ohno Michihiro

  公开号：US20100016319A1

  公开（公告）日：2010-01-21

  This invention relates to a pharmaceutical comprising as an effective ingredient an arylmethylene urea exemplified by the following formula: or a pharmaceutically acceptable salt thereof. The arylmethylene urea and the pharmaceutically acceptable salts thereof are useful for therapy or prophylaxis of inflammatory bowel disease and overactive bladder.

  本发明涉及一种药物，其有效成分为以下式子所示的芳基亚甲基脲或其药学上可接受的盐： 该芳基亚甲基脲及其药学上可接受的盐可用于治疗或预防炎症性肠病和过度活跃的膀胱。
• TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
  申请人：CADILA HEALTHCARE LIMITED

  公开号：EP1781668A2

  公开（公告）日：2007-05-09
• SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1966194A2

  公开（公告）日：2008-09-10
• Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
  申请人：Antel Jochen

  公开号：US20070254862A1

  公开（公告）日：2007-11-01

  Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a K ATP channel modulator; and (ii) a CB x modulator. Also described herein are methods of making and using these compositions.
• TDO2 and IDO1 Inhibitors
  申请人：Genentech, Inc.

  公开号：US20200123163A1

  公开（公告）日：2020-04-23

  Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.